- CITATIONS: 1
|Application ||WB, E|
|Other Accession||Q63379, P03966|
|Calculated MW||49561 Da|
|Antigen Region||322-351 aa|
|Other Names||N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37, MYCN, BHLHE37, NMYC|
|Target/Specificity||This MYCN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 322-351 amino acids from the C-terminal region of human MYCN.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MYCN Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Positively regulates the transcription of NCYM in neuroblastoma cells (PubMed:24391509).|
|Tissue Location||Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level)|
Provided below are standard protocols that you may find useful for product applications.
MYCN is a member of the MYC family and a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of its gene is associated with a variety of tumors, most notably neuroblastomas.
Combaret,V., Pediatr Blood Cancer 53 (3), 329-331 (2009)
Alvarez-Rodriguez,R., J. Cell. Sci. 122 (PT 5), 595-599 (2009)
Jacobs,J.F., BMC Cancer 9, 239 (2009)
If you have any additional inquiries please email technical services at email@example.com.